FDA seeks feedback on potential regulatory approaches for generative AI-enabled medical devices
The Food and Drug Administration is seeking public feedback on a discussion paper released today on potential regulatory approaches for generative artificial intelligence-enabled medical devices. The paper includes considerations for risk assessment, premarket evaluation, post-market monitoring and other areas. The agency intends to gather early stakeholder input and advance broader discussion on policy frameworks for generative AI. The FDA said comments must be submitted by Oct. 19.
Related News Articles
Headline
The Agency for Healthcare Research and Quality Oct. 7 announced the launch of the Super Intelligence for Healthcare Improvement Initiative, a two-part…
Headline
An AHA blog published Oct. 5 responds to a Blue Cross Blue Shield Association report suggesting that hospitals’ use of artificial intelligence-enabled…
Headline
The AHA provided comments Sept. 30 to the Senate Homeland Security and Governmental Affairs Subcommittee on Disaster Management, District of Columbia and…
Headline
Two executive orders on artificial intelligence were released Sept. 29 by the White House. One announced a new website that will use AI to deliver federal…
Headline
The Food and Drug Administration released draft guidance Sept. 24 that includes recommendations on non-clinical testing, clinical data and labeling for…
Headline
In this conversation, John Riggi, AHA national advisor for cybersecurity and risk, and Scott Gee, AHA deputy national advisor for cybersecurity and risk, break…